Comparing Scholar Rock (SRRK) and Its Competitors
Scholar Rock (NASDAQ: SRRK) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Scholar Rock to similar businesses based on the strength of its profitability, valuation, risk, earnings, institutional ownership, analyst recommendations and dividends.
Insider & Institutional Ownership
51.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of current ratings for Scholar Rock and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Scholar Rock Competitors||829||2759||6038||260||2.58|
Scholar Rock currently has a consensus price target of $27.33, suggesting a potential upside of 60.88%. As a group, “Biological products, except diagnostic” companies have a potential upside of 30.21%. Given Scholar Rock’s stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than its peers.
This table compares Scholar Rock and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Scholar Rock Competitors||-5,144.22%||-64.24%||-27.96%|
Valuation & Earnings
This table compares Scholar Rock and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Scholar Rock||$380,000.00||-$49.33 million||-5.38|
|Scholar Rock Competitors||$897.63 million||$190.37 million||-1.12|
Scholar Rock’s peers have higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Scholar Rock beats its peers on 7 of the 12 factors compared.
Scholar Rock Company Profile
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, an inhibitor of the activation of transforming growth factor beta-1 to treat cancers resistant to checkpoint blockade therapies. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.